Metabolic Signatures and Biomarkers in Schizophrenia

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

We plan to use a metabolomics lipid platform to map biochemical signatures in unmedicated schizophrenic patients prior to and 4 weeks post treatment with the antipsychotic drug aripiprazole and compare that to lipid perturbations induced by risperidone. These drugs have inherently different risk for metabolic adverse effects and patients respond to them differently. Metabolic signatures for the drugs capture significant biochemical information that could explain part of the basis for varied drug response within individuals and will highlight pathways implicated in drug action and in disease pathogenesis possibly enabling new drug design strategies. In addition, we will compare patients to healthy controls at baseline in regard lipid profiles.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Duke University
• Collaborator: Bristol-Myers Squibb
• Treatments: Aripiprazole; Risperidone

Criteria

Inclusion Criteria:

• Age 18-60 years

• Diagnosis of schizophrenia

• Actively psychotic

• No more than a single dose of antipsychotic in the preceding 2 weeks

Exclusion Criteria:

• Mental retardation, epilepsy or history of head trauma

• Substance use disorder that explains the majority of the psychopathology

• Pregnant or lactating females